

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) DECEMBER 22, 1995

ENZON, INC.

(Exact name of registrant as specified in its charter)

DELAWARE	0-12957	22-237286
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification)

20 KINGSBRIDGE ROAD, PISCATAWAY, NEW JERSEY	08854
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code (908) 980-4500

(Former name or former address, if changed since last report)

ITEM 5. OTHER EVENTS

Enzon, Inc. ("Enzon" or the "Company") has granted Rhone-Poulenc Rorer Inc. ("RPR") a worldwide, non-exclusive license to use Enzon's Single-Chain Antigen-Binding ("SCA") protein technology for intracellular expression of SCA proteins and for targeted vectors in the field of cell and gene therapy. RPR Gencell, the cell and gene therapy division of RPR, is planning to apply this technology to its in vivo and ex vivo gene therapy programs in cancer, cardiovascular disease and immunology. RPR paid Enzon a \$1,000,000 license fee and will make additional payments upon the achievement of specified product development milestones. RPR will also pay Enzon a royalty based upon sales of products incorporating the Enzon technology.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 7, 1996

ENZON, INC.
(Registrant)

By: /S/ KENNETH J. ZUERBLIS
Kenneth J. Zuerblis
Vice President, Finance
and Chief Financial Officer